Checkmate Pharmaceuticals
Developing a new approach for cancer immunotherapy.
Employees
Enterprise value
$340—510m
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $250m | Acquisition | |
| Total Funding | 000k | ||
F-Prime(exited)
Sofinnova Partners(exited)
venBio Partners(exited)
Sofinnova Investments(exited)
Decheng Capital(exited)
Longitude Capital(exited)
Novo Holdings(exited)
Medicxi(exited)
Omega Funds(exited)
Clough Capital Partners(exited)
Sectoral Asset Management(exited)
BrightEdge(exited)
Eight Roads Ventures(exited)
Novo Seeds(exited)
Related Content
Notes (0)
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.